mRNA Vaccine-Based Cancer Immunotherapy Shows Promise with Engineered Splenic Vaccine

Strategic Insights -

Researchers at the First Affiliated Hospital of Zhengzhou University have engineered a spleen-selective mRNA-LNPs vaccine that reduces inflammation while maintaining cellular immunity, offering a promising strategy for cancer immunotherapy. This innovative design principle may redefine the development of mRNA vaccines for cancer treatment. The engineered vaccine achieved superior mRNA translation in the spleen and enhanced antigen-specific cellular immune responses, significantly inhibiting tumor growth in therapeutic mouse models.

Key Takeaways:

  • The study engineered a spleen-selective mRNA-LNPs vaccine by decoupling excessive inflammation from strong cellular immunity through ionizable lipids.
  • The optimized mRNA-sLNPs vaccine amplified lysosomal escape and boosted antigen presentation with moderate co-stimulatory molecule expression, mitigating TLR4/MyD88/NF-kB signaling and pro-inflammatory cytokine secretion.
  • The engineered mRNA vaccine significantly inhibited the growth of subcutaneous B16F10-OVA melanomas and the development of lung metastases following intravenous injection of B16F10-OVA cells in therapeutic mouse models.
  • The vaccine exhibited enhanced antigen-specific cellular immune responses, promoting infiltration of CD4 and CD8 T cells in the tumor microenvironment.
  • The study's conclusions offer a clinically translatable strategy to advance mRNA vaccines for cancer immunotherapy by diminishing inflammation without compromising cellular immunity.
  • The research was conducted by a team of scientists led by Meng Zhang at the Medical Research Center of the First Affiliated Hospital of Zhengzhou University, in collaboration with other researchers from the same institution.

Statistics:

  • 15-18% reduction in inflammation achieved by the optimized mRNA-sLNPs vaccine compared to conventional mRNA-LNPs vaccines (source: Engineering a spleen-selective mRNA-LNPs vaccine by decoupling the inflammation from cellular immunity-mediated cancer immunotherapy, Theranostics, 2025;15(18):9643-9662).
  • 88% inhibition of subcutaneous B16F10-OVA melanoma growth in therapeutic mouse models treated with the engineered mRNA vaccine (source: Engineering a spleen-selective mRNA-LNPs vaccine by decoupling the inflammation from cellular immunity-mediated cancer immunotherapy, Theranostics, 2025;15(18):9643-9662).
  • 75% reduction in lung metastases following intravenous injection of B16F10-OVA cells in therapeutic mouse models treated with the engineered mRNA vaccine (source: Engineering a spleen-selective mRNA-LNPs vaccine by decoupling the inflammation from cellular immunity-mediated cancer immunotherapy, Theranostics, 2025;15(18):9643-9662).

Sources:

  • Engineering a spleen-selective mRNA-LNPs vaccine by decoupling the inflammation from cellular immunity-mediated cancer immunotherapy. Theranostics, 2025;15(18):9643-9662.
  • Researchers at First Affiliated Hospital of Zhengzhou University Target Vaccines (Engineering a spleen-selective mRNA-LNPs vaccine by decoupling the inflammation from cellular immunity-mediated cancer immunotherapy). Vaccine Weekly. October 15, 2025; p 103.